Trial Search Results

A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer

The primary purpose of this study is to evaluate the ability of oral triamcinalone given twice a day to patients with androgen independent prostate cancer to produce a sustained biochemical response. Secondary goals are to describe the safety and tolerability at this dose and schedule, to determine the time to sustained biochemical response, to determine the duration of biochemical response, to determine the time to disease progression.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: United States Department of Defense

Stanford Investigator(s):


  • Drug: Oral Triamcinalone


Phase 1


Inclusion Criteria:

   - 18 years of age and older

   - Histologically documented adenocarcinoma of prostate

   - Currently receiving LHRH agonists with castrate levels of testosterone or who have had
   an orchiectomy

   - Must have had a rise in PSA despite anti androgen withdrawal

   - Exhibit 2 consecutive rise in PSA after the last hormonal manipulation

   - Minimum PSA of greater than 5 KPS greater than 80%

   - Normal cortisol level at entry

   - Life expectancy greater than 6 months

   - Provide written consent pursuant to regulatory requirements prior to initiation of
   study procedure

Exclusion criteria:

   - Younger than 18 years

   - Patients without prostate cancer

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Denise Haas